Leede Financial Forecasts TSE:ONC FY2024 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Leede Financial issued their FY2024 EPS estimates for Oncolytics Biotech in a research note issued to investors on Wednesday, November 13th. Leede Financial analyst D. Loe forecasts that the company will post earnings per share of ($0.34) for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.05) EPS.

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday.

Oncolytics Biotech Stock Performance

TSE:ONC opened at C$1.38 on Monday. Oncolytics Biotech has a fifty-two week low of C$1.15 and a fifty-two week high of C$2.32. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The company has a 50 day moving average price of C$1.50 and a 200 day moving average price of C$1.45. The stock has a market capitalization of C$106.07 million, a P/E ratio of -3.63 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.